Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

PRECOS Launches PUMA at AACR 2013

Published: Monday, April 08, 2013
Last Updated: Monday, April 08, 2013
Bookmark and Share
Company launches portfolio of techniques and models of acquired resistance to targeted agents and standards of care used in oncology.

Preclinical Oncology Services Limited (PRECOS) has launched PRECOS Unique Models of Acquired resistance (PUMA) at the AACR annual meeting (Washington DC, April 6th - 10th).

Derived from cell lines and proprietary PDX (Patient-Derived Xenograft) models, PUMA models provide a unique bespoke collection of clinically relevant and validated models of resistance, as well as the techniques and expertise to develop client specific models of acquired resistance to chemotherapeutics and targeted agents.

Such models are a major advancement for pharmaceutical and biotech companies running oncology R&D programmes and will enhance success rates during the critical phase of transitioning from pre-clinical to clinical evaluation of new drug candidates.

The first available examples of PUMA models are in specific lung cancer subsets where PRECOS has previously developed and characterized a focused panel of PDX lung cancer models derived directly from Caucasian patient tumour material - PRECOS’ unique model atlas LION (Lung In ONcology).

By repeatedly challenging relatively homogeneous cell line populations (CTX models) and heterogeneous tumours from PDX models across several passages, PRECOS is able to compare and contrast behaviour such as growth characteristics with gene expression and pathway analysis, response to chemotherapeutics and targeted agents.

It is also possible to assess the effect of varying treatment regimens and dosing strategies including drug holidays or combination therapies.

This allows panels of tumour subset specific models to be built which are able to mimic patients and their responses to treatment regimes in the clinic.

PRECOS is committed to further developing PUMA and is continuing to progress the techniques to provide customized services.

This will enable its clients to build models based on the characteristics of diverse cancer cell types which can offer insights for designing optimal treatment strategies around their pre-clinical candidates prior to product development and clinical trials.

“As oncology R&D progresses, there is an increasingly critical need for more clinically-relevant predictive pre-clinical models in order to overcome the high attrition rates of agents entering clinical trials,” said Dr Martin Page, Scientific Consultant, PRECOS.

Dr Page continued, “All new agents entering phase 1 clinical trials will be tested in cancer patients that have likely become resistant to a range of targeted and chemotherapeutic agents. PUMA is part of our PREdict platform, and offers PRECOS’ clients pre-clinical models that are authentic counterparts of the drug-resistant tumour subsets seen in the clinic, rather than drug-naive models. PRECOS’ latest portfolio offers specialist drug resistant pre-clinical models with responses of higher predictability with outcomes that can be seen during clinical testing.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Latest Advances in PDX Modelling for Oncology Drug Discovery
PRECOS' co-presentation with Crown Bioscience from Tumor Models Boston 2013 meeting available for download.
Friday, September 13, 2013
PRECOS Doubles Capacity and Appoints New Senior Scientific Staff to Accommodate Significant Growth
The company has expanded to accommodate existing and anticipated growth in line with its leadership in oncology drug discovery.
Tuesday, February 15, 2011
PRECOS Secures Multi Year Global Service Agreement with Leading Pharmaceutical Company
Preclinical Oncology Services Limited (PRECOS) has signed a significant service agreement with a leading global pharmaceutical company Janssen Pharmaceutica N.V. The contract will see PRECOS provide clinical tumour material, tumour model development, target validation and drug efficacy work to support Janssen’s oncology drug discovery, development and biomarker programmes.
Thursday, November 25, 2010
Scientific News
Promising Drug Combination for Advanced Prostate Cancer
A new drug combination may be effective in treating men with metastatic prostate cancer. Preliminary results of this new approach are encouraging and have led to an ongoing international study being conducted in 196 hospitals worldwide.
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Scroll Up
Scroll Down

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos